Is there a reversal of reverse epidemiology in renal transplant recipients?

Seminars in Dialysis

Volumn 20, Issue 6, 2007, Pages 544-548

  Chavalitdhamrong, Disaya ^a   Danovitch, Gabriel M ^a   Bunnapradist, Suphamai ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; HOMOCYSTEINE;

BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; EPIDEMIOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; KIDNEY TRANSPLANTATION; OBESITY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CREATININE; EPIDEMIOLOGIC STUDIES; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; OBESITY; RENAL DIALYSIS; RISK FACTORS;

EID: 35948947892     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00351.x     Document Type: Review

References (73)

1. Rabbat CG, Thorpe KE, Russell JD, Churchill DN : Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 11 : 917 922, 2000
2. West M, Sutherland DE, Matas AJ : Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. Transplantation 62 : 1029 1030, 1996
3. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G : Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60 : 451 457, 1995
4. Diaz JM, Sainz Z, Guirado LL, Ortiz-Herbener F, Picazo M, Garcia-Camin R, Palou J, Alcaraz A, Sola R : Risk factors for cardiovascular disease after renal transplantation. Transplant Proc 35 : 1722 1724, 2003
5. Rigatto C : Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial 16 : 106 110, 2003
6. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ : Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7 : 158 165, 1996
7. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK : Long-term survival in renal transplant recipients with graft function. Kidney Int 57 : 307 313, 2000
8. Foley RN, Parfrey PS, Sarnak MJ : Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9 (12 Suppl S16 S23, 1998
9. Baigent C, Burbury K, Wheeler D : Premature cardiovascular disease in chronic renal failure. Lancet 356 : 147 152, 2000
10. Sung RS, Althoen M, Howell TA, Merion RM : Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. Transplantation 70 : 1049 1054, 2000
11. Kasiske BL, Chakkera HA, Roel J : Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 : 1735 1743, 2000
12. Ostovan MA, Fazelzadeh A, Mehdizadeh AR, Razmkon A, Malek-Hosseini SA : How to decrease cardiovascular mortality in renal transplant recipients. Transplant Proc 38 : 2887 2892, 2006
13. Pliakogiannis T, Trpeski L, Taskapan H, Shah H, Ahmad M, Fenton S, et al. : Reverse epidemiology in peritoneal dialysis patients: the Canadian experience and review of the literature. Int Urol Nephrol 39 : 281 298, 2007
14. Kalantar-Zadeh K, Kopple JD : Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 151 : 57 69, 2006
15. Nurmohamed SA, Nube MJ : Reverse epidemiology: paradoxical observations in haemodialysis patients. Neth J Med 63 : 376 381, 2005
16. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD : Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 45 : 811 817, 2005
17. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD : Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 : 793 808, 2003
18. Abbott KC, Glanton CW, Agodoa LY : Body mass index and enrollment on the renal transplant waiting list in the United States. J Nephrol 16 : 40 48, 2003
19. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, et al. : Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 40 : 307 314, 2002
20. Kakiya R, Shoji T, Tsujimoto Y, Tatsumi N, Hatsuda S, Shinohara K, et al. : Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 70 : 549 556, 2006
21. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, et al. : Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 46 : 489 500, 2005
22. Byers T : Body weight and mortality. N Engl J Med 333 : 723 724, 1995
23. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ : Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 31 : 997 1006, 1998
24. Baum CL : Weight gain and cardiovascular risk after organ transplantation. JPEN J Parenter Enteral Nutr 25 : 114 119, 2001
25. el-Agroudy AE, Wafa EW, Gheith OE, Shehab el-Dein AB, Ghoneim MA : Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation 77 : 1381 1385, 2004
26. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM : Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 5 : 2710 2718, 2005
27. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. : Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345 : 1291 1297, 2001
28. Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, et al. : Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 51 : 1212 1217, 1997
29. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. : "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 54 : 561 569, 1998
30. Opelz G, Dohler B : Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 5 : 2725 2731, 2005
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 : 145 153, 2000
32. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 : 1004 1010, 2002
33. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 : 1456 1462, 1993
34. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861 869, 2001
35. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. : Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17 : 889 899, 2006
36. Opelz G, Zeier M, Laux G, Morath C, Dohler B : No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17 : 3257 3262, 2006
37. Andres A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM : Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Transplant Proc 38 : 2419 2423, 2006
38. Shaten BJ, Kuller LH, Neaton JD : Association between baseline risk factors, cigarette smoking, and CHD mortality after 10.5 years. MRFIT Research Group. Prev Med 20 : 655 659, 1991
39. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, et al. : Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31 : 103 110, 1982
40. Lowrie EG, Lew NL : Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 : 458 482, 1990
41. Volpato S, Leveille SG, Corti MC, Harris TB, Guralnik JM : The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc 49 : 1142 1147, 2001
42. Avram MM, Bonomini LV, Sreedhara R, Mittman N : Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis 28 : 910 917, 1996
43. Kobashigawa JA, Kasiske BL : Hyperlipidemia in solid organ transplantation. Transplantation 63 : 331 338, 1997
44. Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmento AM, et al. : Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrol Dial Transplant 12 : 2140 2143, 1997
45. Moore R, Hernandez D, Valantine H : Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf 24 : 755 766, 2001
46. Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM : A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 18 : 274 280, 2004
47. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. : Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 : 2024 2031, 2003
48. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. : Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5 : 2929 2936, 2005
49. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. : Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17 : 2034 2047, 2006
50. Gamba G, Mejia JL, Saldivar S, Pena JC, Correa-Rotter R : Death risk in CAPD patients. The predictive value of the initial clinical and laboratory variables. Nephron 65 : 23 27, 1993
51. Kaizu Y, Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K, et al. : Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 42 : 295 302, 2003
52. Muntner P, He J, Hamm L, Loria C, Whelton PK : Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 : 745 753, 2002
53. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296 1305, 2004
54. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al. : The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 164 : 969 976, 2004
55. Meier-Kriesche HU, Baliga R, Kaplan B : Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75 : 1291 1295, 2003
56. Abbott KC, Bucci JR, Cruess D, Taylor AJ, Agodoa LY : Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 13 : 2560 2569, 2002
57. Fellstrom B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, et al. : Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 5 : 1986 1991, 2005
58. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B : Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 4 : 1662 1668, 2004
59. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, et al. : Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 57 : 1727 1735, 2000
60. Suliman ME, Lindholm B, Barany P, Bergstrom J : Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin Chem Lab Med 39 : 734 738, 2001
61. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE : Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 : 230 236, 1997
62. Meleady RA, Graham IM : Homocysteine as a risk factor for coronary artery disease. J Cardiovasc Risk 2 : 216 221, 1995
63. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. : Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94 : 2743 2748, 1996
64. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al. : Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61 : 609 614, 2002
65. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, et al. : Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6 : 121 125, 1995
66. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP : An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 60 : 1106 1113, 2001
67. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, et al. : Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9 : 1103 1108, 1994
68. Franke S, Muller A, Sommer M, Busch M, Kientsch-Engel R, Stein G : Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 59 : 88 97, 2003
69. Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG : Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2 : 308 313, 2002
70. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM : Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11 : 134 137, 2000
71. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Jacques PF, Dworkin L, et al. : Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 69 : 2128 2131, 2000
72. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, et al. : Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 127 : 1089 1092, 1997
73. Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, et al. : Rationale and design of the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial. Am Heart J 152 : 448 e1 448 e7, 2006